Practice Areas

Corporate
array(3) { [0]=> object(WP_Post)#1702 (24) { ["ID"]=> int(243) ["post_author"]=> string(1) "1" ["post_date"]=> string(19) "2014-10-06 21:45:51" ["post_date_gmt"]=> string(19) "2014-10-06 21:45:51" ["post_content"]=> string(0) "" ["post_title"]=> string(13) "Daniel B. Eng" ["post_excerpt"]=> string(0) "" ["post_status"]=> string(7) "publish" ["comment_status"]=> string(6) "closed" ["ping_status"]=> string(6) "closed" ["post_password"]=> string(0) "" ["post_name"]=> string(9) "dan-b-eng" ["to_ping"]=> string(0) "" ["pinged"]=> string(0) "" ["post_modified"]=> string(19) "2017-08-16 16:42:49" ["post_modified_gmt"]=> string(19) "2017-08-16 16:42:49" ["post_content_filtered"]=> string(0) "" ["post_parent"]=> int(0) ["guid"]=> string(37) "http://weinwp.dev/attorneys/dan-e-eng" ["menu_order"]=> int(0) ["post_type"]=> string(9) "attorneys" ["post_mime_type"]=> string(0) "" ["comment_count"]=> string(1) "0" ["filter"]=> string(3) "raw" } [1]=> object(WP_Post)#1704 (24) { ["ID"]=> int(245) ["post_author"]=> string(1) "1" ["post_date"]=> string(19) "2014-10-06 21:45:51" ["post_date_gmt"]=> string(19) "2014-10-06 21:45:51" ["post_content"]=> string(0) "" ["post_title"]=> string(14) "David C. Adams" ["post_excerpt"]=> string(0) "" ["post_status"]=> string(7) "publish" ["comment_status"]=> string(6) "closed" ["ping_status"]=> string(6) "closed" ["post_password"]=> string(0) "" ["post_name"]=> string(13) "david-c-adams" ["to_ping"]=> string(0) "" ["pinged"]=> string(0) "" ["post_modified"]=> string(19) "2017-08-15 23:54:58" ["post_modified_gmt"]=> string(19) "2017-08-15 23:54:58" ["post_content_filtered"]=> string(0) "" ["post_parent"]=> int(0) ["guid"]=> string(41) "http://weinwp.dev/attorneys/david-c-adams" ["menu_order"]=> int(0) ["post_type"]=> string(9) "attorneys" ["post_mime_type"]=> string(0) "" ["comment_count"]=> string(1) "0" ["filter"]=> string(3) "raw" } [2]=> object(WP_Post)#1706 (24) { ["ID"]=> int(283) ["post_author"]=> string(1) "1" ["post_date"]=> string(19) "2014-10-06 21:45:55" ["post_date_gmt"]=> string(19) "2014-10-06 21:45:55" ["post_content"]=> string(0) "" ["post_title"]=> string(15) "Mike De Angelis" ["post_excerpt"]=> string(0) "" ["post_status"]=> string(7) "publish" ["comment_status"]=> string(6) "closed" ["ping_status"]=> string(6) "closed" ["post_password"]=> string(0) "" ["post_name"]=> string(15) "mike-de-angelis" ["to_ping"]=> string(0) "" ["pinged"]=> string(0) "" ["post_modified"]=> string(19) "2017-07-24 23:01:36" ["post_modified_gmt"]=> string(19) "2017-07-24 23:01:36" ["post_content_filtered"]=> string(0) "" ["post_parent"]=> int(0) ["guid"]=> string(43) "http://weinwp.dev/attorneys/mike-de-angelis" ["menu_order"]=> int(0) ["post_type"]=> string(9) "attorneys" ["post_mime_type"]=> string(0) "" ["comment_count"]=> string(1) "0" ["filter"]=> string(3) "raw" } }

Attorneys

Longtime Weintraub Client, ThermoGenesis, Issued Press Release Regarding Definitive Merger Agreement

July, 16, 2013

Download: Press-Release-Cesca-Merger-Final.pdf

RANCHO CORDOVA AND LOS ANGELES, CA – July 16, 2013 – ThermoGenesis Corp. (NASDAQ: KOOL) (“ThermoGenesis”), a leading supplier of enabling technologies for the
processing and storage of stem cells and other biological tissues, and TotipotentRx Corporation (“TotiRx”), a privately held California Corporation, which specializes in developing cell-based
therapies in the field of regenerative medicine and is the exclusive provider of cell-based product and services to the Fortis Healthcare System, today announced that they have entered into a
definitive merger agreement. The combined company is expected to become one of the first fully integrated regenerative medicine companies, developing clinically validated, commercially
scalable, point-of-care cell therapies for major therapeutic markets, including orthopedic, cardiovascular and neurologic indications.

Under terms of the agreement, ThermoGenesis will issue approximately 12,491,000 shares of its common stock to TotiRx which equates to a value of approximately $18.6 million, based on
ThermoGenesis’ closing stock price of $1.49 on July 15, 2013. The merger agreement has been unanimously approved by the board of directors of each company. The transaction is expected to
close in the fourth quarter of calendar year 2013 and is subject to customary closing conditions, certain financial conditions, regulatory approvals and approval by the shareholders of
ThermoGenesis and TotiRx. The combined company is expected to be named Cesca Therapeutics (“Clinical Excellence in Stem Cell Applications”) and will continue to trade on
NASDAQ under the ticker symbol KOOL.

To view the full press release click the link above.